Comirnaty™ (Pfizer/BioNTech) is a vaccine that protects against COVID-19 disease caused by the SARS-CoV-2 virus.

How Comirnaty is made and what it contains

On this page you will find:

  • What type of vaccine the Comirnaty vaccine is
  • How mRNA vaccine technology works
  • How the vaccine is made
  • What the vaccine contains

Visit page: How Comirnaty is made and what it contains.

How the vaccine works and the protection it provides

On this page you will find:

  • How mRNA vaccines, like Comirnaty, work
  • How protective is this vaccine?

Visit page: How the vaccine works and the protection it provides.

 

References

  • Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med. 2020;383(27):2603-15.
  • Thompson M, Burgess J, Naleway A, et al. Interim Estimates of Vaccine Effectiveness of BNT162b2 and mRNA-1273 COVID-19 Vaccines in Preventing SARS-CoV-2 Infection Among Health Care Personnel, First Responders, and Other Essential and Frontline Workers — Eight U.S. Locations, December 2020–March 2021. MMWR Morb Mortal Wkly Rep, 2021.
  • Dagan N, Barda N, Kepten E, Miron O, Perchik S, Katz MA, et al. BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting. New England Journal of Medicine. 2021.
  • Clancy, S. & Brown, W. (2008) Translation: DNA to mRNA to Protein. Nature Education 1(1):101
  • Comirnaty data sheet https://www.medsafe.govt.nz/profs/Datasheet/c/comirnatyinj.pdf
  • Petousis-Harris H. Assessing the Safety of COVID-19 Vaccines: A Primer. Drug Saf. 2020;43(12):1205-10.
  • Law B, Sturkenboom M. D2. 3 Priority list of adverse events of special interest: COVID-19. The Brighton Collaboration. https://brightoncollaboration.us/wp-content/uploads/2020/06/SPEAC_D2.3_V2.0_COVID-19_20200525_public.pdf.
  • Shimbabukuro T, CDC-COVID-19 Vaccine Task Force. COVID-19 vaccine safety update. March 2021. 2021 1 March 2021.Available from: https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2021-02/28-03-01/05-covid-Shimabukuro.pdf